Matinas BioPharma
MTNB
48 hedge funds and large institutions have $15.1M invested in Matinas BioPharma in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
7% more funds holding
Funds holding: 45 → 48 (+3)
0.01% more ownership
Funds ownership: 0.23% → 0.25% (+0.01%)
16% less capital invested
Capital invested by funds: $18M → $15.1M (-$2.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMG
Alliance Wealth Management Group
Flemington,
New Jersey
|
+$535K |
| 2 |
State Street
Boston,
Massachusetts
|
+$301K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$252K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$89.6K |
| 5 |
Morgan Stanley
New York
|
+$78.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$161K |
| 2 |
Millennium Management
New York
|
-$86K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$81.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$61K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$43.6K |
MTNB Hedge Fund Activity: Q3 2017 in Review
48 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2017, worth a combined $15.1M — down 16% from $18M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MTNB positions and 3 closed out — a net gain of 4 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Alliance Wealth Management Group, adding an estimated $535K. The largest seller was Royal Bank of Canada, cutting an estimated $161K.
- 48 institutional investors held Matinas BioPharma (MTNB) as of Q3 2017, up from 45 in Q2 2017.
- Funds reported $15.1M of Matinas BioPharma stock for Q3 2017, down 16% quarter-over-quarter.
- 7 funds opened new Matinas BioPharma positions in Q3 2017 and 3 closed out, a net change of +4 holders.
- The largest Matinas BioPharma buyer in Q3 2017 was Alliance Wealth Management Group, an estimated $535K added.
- The largest Matinas BioPharma seller in Q3 2017 was Royal Bank of Canada, an estimated $161K sold.
Based on aggregated 13F filings for Q3 2017.